About
Structure-based Drug Design for Kinase Targeting
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
1,799
By Phase
PHASE3: 1PHASE1: 1PHASE1/PHASE2: 2
By Status
RECRUITING: 4AVAILABLE: 2
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06765109Lead Sponsor
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
PHASE3Recruiting
450 participants
Started: Jul 17, 2025 · Completed: Dec 31, 2029
NCT06521554Lead Sponsor
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
PHASE1Recruiting
150 participants
Started: Jul 18, 2024 · Completed: Mar 31, 2026
NCT05384626Lead Sponsor
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
PHASE1/PHASE2Recruiting
840 participants
Started: Jun 9, 2022 · Completed: Jan 31, 2028
NCT05118789Lead Sponsor
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
PHASE1/PHASE2Recruiting
359 participants
Started: Jan 4, 2022 · Completed: Oct 31, 2026
NCT06797362Lead Sponsor
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
N/AAVAILABLE
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...